Intelligence Driven Advisers’s Pfizer PFE Stock Holding History

Intelligence Driven Advisers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,593	Closed	-$208K	–	92
2019 Q4	$208K	Buy	+5,593	New	+$199K	0.09%	85
2019 Q3	–	Sell	-5,671	Closed	-$233K	–	104
2019 Q2	$233K	Sell	5,671 -147	-3%	-$5.84K	0.11%	94
2019 Q1	$234K	Buy	+5,818	New	+$233K	0.13%	84

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Intelligence Driven Advisers's PFE Position: Q1 2020 in Review

Intelligence Driven Advisers sold out of Pfizer (PFE) in Q1 2020, closing a stake of 5,593 shares — an estimated $208K sold.

Intelligence Driven Advisers first reported a position in PFE in Q1 2019 and held it in 3 quarters. The position peaked at $234K in Q1 2019. 2,436 funds tracked by Wall St. Rank hold PFE as of Q1 2020.

Intelligence Driven Advisers reported no remaining Pfizer position as of Q1 2020 after selling out during the quarter.
Intelligence Driven Advisers sold 5,593 Pfizer shares in Q1 2020, an estimated $208K.
Intelligence Driven Advisers first reported a position in Pfizer in Q1 2019 and held it in 3 quarters.
Intelligence Driven Advisers's Pfizer position peaked at $234K in Q1 2019.
2,436 funds tracked by Wall St. Rank held Pfizer as of Q1 2020.

Based on Intelligence Driven Advisers's 13F filing for Q1 2020, filed 4 Sep 2020.